Lapatinib
| Code | Size | Price |
|---|
| SYN-1052-M100 | 100 mg | Enquire |
Quantity:
| SYN-1052-M001 | 1 mg | £69.00 |
Quantity:
| SYN-1052-M005 | 5 mg | £80.00 |
Quantity:
| SYN-1052-M010 | 10 mg | £92.00 |
Quantity:
| SYN-1052-M050 | 50 mg | £233.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
GW-572016
Appearance:
Solid.
CAS:
231277-92-2
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07
Hazards:
H303, H317, H333
InChi:
InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)
InChiKey:
BCFGMOOMADDAQU-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 231277-92-2. Formula: C29H26ClFN4O4S. MW: 581.1. Lapatinib is an ATP-competitive epidermal growth factor receptor (EGFR) and HER2/neu (ErbB-2) dual tyrosine kinase inhibitor, with IC(50) values of 10.8 and 9.2nM respectively. It is an orally active drug for treatment of breast cancer and other solid tumors.
Molecular Formula:
C29H26ClFN4O4S
Molecular Weight:
581.1
Package Type:
Plastic Vial
Precautions:
P261, P272, P280, P302, P352, P333, P313, P321, P363, P501
Product Description:
Lapatinib is an ATP-competitive epidermal growth factor receptor (EGFR) and HER2/neu (ErbB-2) dual tyrosine kinase inhibitor, with IC(50) values of 10.8 and 9.2nM respectively. It is an orally active drug for treatment of breast cancer and other solid tumors.
Purity:
>95%
Signal word:
Warning
Solubility Chemicals:
Soluble in DMSO or ethanol.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways: W. Xia, et al.; Oncogene 21, 6255 (2002)